Krystal BiotechvsMerck & Company

KRYS and MRK stock compared: price, dividend, valuation and results, from SEC filings.

KRYS

Krystal Biotech, Inc.

$298.55

Value $8.7B

+0.22%
KRYS's page

MRK

Merck & Company, Inc.

$143.37

Value $354B

-0.75%
MRK's page

Krystal Biotech (KRYS) has a market value of $8.7B and Merck & Company (MRK) $354B. Over the last year, with dividends, KRYS moved +44.8% and MRK +58.8%. The P/E is 38.8 for KRYS and 144.5 for MRK. Dividend yield: KRYS none, MRK 2.37%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    KRYS$8.7B

    MRK$354B

    MRK is 41 times KRYS

  • Revenue, 12 months

    KRYS$470M

    MRK$67.4B

    MRK is 143 times KRYS

  • Net income, 12 months

    KRYS$225M

    MRK$2.5B

    MRK is 11 times KRYS

  • Operating margin

    KRYS48.4%

    MRK–

  • ROIC

    KRYS15.4%

    MRK3.9%

    11.5 points apart

  • P/E

    KRYS38.8

    MRK144.5

    MRK is 3.7 times KRYS

  • Dividend yield

    KRYS0.0%

    MRK2.4%

    2.4 points apart

  • 5-year return

    KRYS+514.0%

    MRK+98.6%

    415.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

KRYS+514.1%

MRK+98.6%

20040060080020222023202420252026
Returns by period
PeriodKRYSWith dividendsMRKWith dividends
1 year since November 14, 2025+44.8%Price +44.8%+58.8%Price +54.3%
3 years since November 17, 2023+186.6%+42.0% a yearPrice +186.6%+54.4%+15.6% a yearPrice +40.9%
5 years since November 16, 2021+514.0%+43.8% a yearPrice +514.0%+98.6%+14.7% a yearPrice +70.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

KRYSKrystal BiotechMRKMerck & Company

Valuation

KRYSMRK
Valuation
Price$298.55$143.37
Market value$8.7B$354B
Enterprise value (EV)$7.8B$399B
P/E38.8144.5
P/E, 5-year median–14.8
P/B6.17.9
EV/EBIT34.483.7
Free cash flow yield3.6%4.2%

Results and growth

KRYSMRK
Results and growth
Revenue, 12 months$470M$67.4B
Net income, 12 months$225M$2.5B
Free cash flow, 12 months$310M$14.7B
Earnings per share, 12 months$7.37$0.98
Revenue growth, year on year33.9%1.3%
Revenue growth a year, past–+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

KRYSMRK
Margins and returns on capital
Gross margin–71.8%
Operating margin48.4%–
Net margin47.9%3.6%
ROIC15.4%3.9%
ROE17.5%5.2%

Balance sheet

KRYSMRK
Balance sheet
Cash$912M$9.7B
Total debt$8.6M$53.8B
Net debt / EBITDA-3.95.7
Interest cover–2.4×

Dividends and buybacks

KRYSMRK
Dividends and buybacks
Dividend yield–2.4%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.4%
Shareholder yield–3.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: KRYS or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Krystal Biotech or Merck & Company?

By market value, Merck & Company ($354B) is about 40.6 times Krystal Biotech ($8.7B), at today's prices.

How did KRYS and MRK stock do over the last 5 years?

Since November 16, 2021, KRYS's price moved +514.0% and MRK's +70.5%. With dividends: KRYS +514.0% (+43.8% a year), MRK +98.6% (+14.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, KRYS or MRK?

The dividend yield at today's price is none for Krystal Biotech and 2.37% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

What is the P/E of KRYS and MRK?

At today's price, the P/E is 38.8 for KRYS and 144.5 for MRK. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Krystal Biotech or Merck & Company?

Over the last twelve months, the net margin was 47.9% for Krystal Biotech and 3.6% for Merck & Company, and the operating margin 48.4% and –. Revenue was $470M and $67.4B.

Which is the better investment, Krystal Biotech or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.